Provides for limitations on the prescribing of opioids
Impact
The implications of HB 192 are notable as it may lead to a significant reduction in the availability of opioids for patients who require them for acute medical conditions. The bill does provide exceptions, allowing more than a seven-day prescription if medically justified, such as in the cases of chronic pain or cancer treatment. Furthermore, it requires practitioners to document the reasons for any exceptions, which may have a significant impact on healthcare practices and patient management strategies across the state.
Summary
House Bill 192 establishes a significant change in the regulation of opioid prescriptions in Louisiana, particularly focusing on limiting prescriptions to a maximum of a seven-day supply. This bill aims to combat opioid misuse and dependency by controlling the quantity of opioids prescribed to patients, especially minors. Under this legislation, medical practitioners are required to consult with patients about the risks associated with opioid use and discuss the potential to prescribe a lesser quantity if deemed appropriate. This law reflects a growing national concern regarding the opioid crisis and seeks to enhance patient safety.
Sentiment
The sentiment surrounding HB 192 appears to reflect caution and a commitment to patient health and safety. Supporters of the bill argue it is a necessary step to mitigate the opioid epidemic by limiting access and ensuring that opioids are prescribed only when absolutely necessary. However, there is a concern among some healthcare providers about the potential for this legislation to complicate care for patients who genuinely need continuous pain management, creating a balance that needs to be carefully navigated.
Contention
Points of contention primarily revolve around the balance between preventing misuse while ensuring adequate pain management for patients. Opponents have raised concerns that overly restrictive prescription limits may hinder the treatment of legitimate medical conditions, resulting in significant patient suffering. Additionally, there could be apprehensions regarding the responsibility and implications placed on physicians, who must navigate the new regulatory landscape while maintaining their patients' trust and care quality.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.